Complete Response to Pembrolizumab as Monotherapy in a Patient with Baseline Stage IV NSCLC with Very High PD-L1 Expression

Pecci ACR graphic
Download (1.62 MB)
General
Complete Response to Pembrolizumab as Monotherapy in a Patient with Baseline Stage IV NSCLC with Very High PD-L1 Expression

Federica Pecci, MD
Italy